Liraglutide

This review article addresses the safety profile of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, specifically in the context of breastfeeding. The authors note that no empirical data are currently available on liraglutide use during lactation. The discussion is grounded in pharmacokinetic reasoning: liraglutide is a large peptide molecule with a molecular weight of 3,751 daltons, which suggests that transfer into breast milk would likely be minimal. Furthermore, even if trace amounts were present in milk, oral absorption by the nursing infant is considered unlikely, as the peptide would probably be degraded by proteolytic enzymes in the infant's gastrointestinal tract. Despite this theoretically low risk, the authors recommend caution when using liraglutide during breastfeeding, with particular attention to newborns and preterm infants, who may have less developed gastrointestinal and metabolic systems. The article acknowledges the absence of clinical or experimental data as a key limitation, meaning conclusions are based on indirect, mechanistic reasoning rather than direct observation or controlled study.

Why this grade: The article contains no original human or animal study data; conclusions are based entirely on theoretical pharmacokinetic reasoning in the absence of any empirical lactation studies.